Fecal Immunochemical Tests Decrease Incidence of Colorectal Cancer and Mortality

Colorectal cancer, intestinal carcinoma, bowel neoplasia, 3D illustration showing malignant tumor in intestine
Researchers sought to determine whether using a fecal immunochemical test would help decrease colorectal cancer and mortality.

Fecal immunochemical test (FIT) screening is effective in reducing the incidence of colorectal cancer (CRC) and mortality, according to study results published in Clinical Gastroenterology and Hepatology.

Various tests are used to screen individuals at average risk for CRC, but experts recommend FITs over guaiac-based fecal occult blood tests (gFOBTs) for FITs’ increased sensitivity in detecting advanced adenomas and CRC. FITs also have a comparable or higher level of specificity due to not being affected by diet, unlike gFOBTs. Up until the current study, data had been limited on the effectiveness of FIT screening compared with no screening for decreasing the incidence of CRC.

For the analysis, researchers reviewed data on CRC incidence and mortality by comparing results of people who had participated in an Italian regional biennial FIT screening program with people who had not. The program started in 2005 with a target population of over 1,000,000 people aged 50 to 69 years. Researchers identified individuals who registered up to December 2016 and calculated self-selection-adjusted incidence rate ratios (IRR) and incidence-based CRC mortality rate ratios (MRR) for program attenders and nonattenders.

Overall, the FIT screening program was associated with a decrease in CRC incidence in men (33%) and women (21%) at 11 years of follow-up. The cohort generated 2,622,131 man-years and 2,887,845 woman-years at risk with 4490 and 3309 CRC cases, respectively. Men, women, and both sexes combined in the attenders group were associated with an incidence rate ratio (IRR) of 0.65, 0.75, and 0.69, respectively. Men had a self-selection-adjusted IRR of 0.67 and women had 0.79. The IRR for stage I, II, III, and IV CRC was 1.35, 0.61, 0.60, and 0.28 for men and 1.64, 0.60, 0.73, and 0.35 for women. The incidence-based CRC mortality rate ratio (MRR) overall was 0.32 for men, 0.40 for women, and 0.35 for both sexes combined, while the adjusted MRR was 0.35 for men and 0.46 for women.

“Our data corroborate the few previous observational longitudinal studies on the effectiveness of FIT screening in reducing CRC incidence,” the study authors noted.


Baldacchini F, Bucchi L, Giuliani O, et al. Effects of attendance to an organized fecal immunochemical test screening program on the risk of colorectal cancer: an observational cohort study. Clin Gastroenterol Hepatol. Published online February 7, 2022. doi:10.1016/j.cgh.2022.01.053.